A growing enthusiasm for therapeutic modulation of this proteostasis network highlights Hsp's and CLU as rational targets because of their multifunctional roles in signaling and transcriptional networks associated with cancer progression and treatment resistance. Here, HSP90B2P is linked to cancer.